N-MID Osteocalcin

• Serum-based assay measuring the N-terminal midfragment of osteocalcin, indicative of bone formation.
• Reflects osteoblastic activity, providing insights into bone formation dynamics.
• Validated for use in human blood samples, ensuring reliable and reproducible measurements.
• Non-invasive tool for assessing bone formation, suitable for routine blood sampling.
• Correlates with bone formation rates in conditions such as osteoporosis and other metabolic bone diseases.
• Useful for monitoring therapeutic response, with changes in N-MID levels reflecting the efficacy of anabolic treatments.
• Facilitates research and development of targeted therapies by providing insights into bone remodeling mechanisms.

The N-MID biomarker assay is designed to quantify the N-terminal midfragment of osteocalcin in serum, serving as a specific indicator of bone formation. Osteocalcin is a non-collagenous protein synthesized by osteoblasts and plays a crucial role in bone mineralization and calcium ion homeostasis. By measuring this fragment, the assay provides a direct assessment of osteoblastic activity and bone formation rates.

This assay has been validated for use in human blood samples, demonstrating its reliability and reproducibility in various clinical and research settings. Elevated serum N-MID levels have been associated with increased bone formation in conditions such as osteoporosis and other metabolic bone diseases. The non-invasive nature of the test makes it suitable for routine monitoring of bone health and the effectiveness of anabolic therapies.

In addition to its clinical applications, the N-MID assay serves as a valuable tool in research, facilitating the study of bone remodeling mechanisms and the development of targeted treatments aimed at modulating bone formation processes.

Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.